Home    Products    Sales Conditions & distributors    Quality controls    Instructions For Use    Links

#ASP-025 FungaDia-Aspergillus Antigen Rapid Test
Rapid test kit for the diagnosis of human invasive aspergillosis

Parasitology and clinical relevance

Aspergillus fumigatus is one of the most ubiquitous of the airborne saprophytic fungi. Humans and animals constantly inhale numerous conidia of this fungus. It is responsible from Invasive Aspergillosis (IA) occuring mainly in neutropenic patients (anticancer treatment), in patients treated with immunosuppressants and corticosteroids (following bone marrow transplantation) and in patients hospitalized in intensive care for severe respiratory disease (influenza, COVID-19). Due to the lack of typical clinical manifestations The detection of galactomannan in serum or BAL is the recommended diagnostic method.


25 determinations of Aspergillus galactomannan antigen in serum and bronchoalveolar lavage (BAL) fluid from patients suspected of Fungal infections using standard methodologies.

The antigens in the sample react with the red-colored nanoparticles and form a complex which is captured by the anti-Aspergillus antibodies present on the membrane (Test line) forming a red line.

CE registration: CH-202201-0057

Sensitivity and specificity

A sensitivity of 78% was found with 49 sera positive with the Aspergillus Ag ELISA Assay Platelia (BioRad).

A sensitivity of 100% was found with 2 BAL positive with the Aspergillus Ag ELISA Assay Platelia (BioRad).  

A specificity of 96% was found with 104 sera negative with the Aspergillus Ag ELISA Assay Platelia (BioRad).  

A specificity of 96% was found with 28 BAL negative with the Aspergillus Ag ELISA Assay Platelia (BioRad).  


25x Aspergillus Galactomanann Detection Test

1x1ml Positive Control (50ng/ml galactomanann)

1x1ml Negative Control

1x3ml Sample treatment solution

1x Instruction for use

Ordering information

#ASP-025 FungaDia-Aspergillus Antigen Rapid Test (25 assays)


Reischies F, Hoenigl M. The role of surgical debridement in different clinical manifestations of invasive aspergillosis. Mycoses 2014; 57 (Suppl 2):1–14.

Eigl S. et al. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. Int J Antimicrob Agents. 2015; 46(4):401–5.

White PL. et al. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol. 2013; 51(5):1510–6.

Hoenigl M. et al. Performance of galactomannan, beta-D-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014; 52(6):2039–45.

Held J. et al. Comparison of a novel Aspergillus lateral-flow device and the Platelia galactomannan assay for the diagnosis of invasive aspergillosis following hematopoietic stem cell transplantation. Infection. 2013; 41(6):1163–9.

Johnson GL. et al. Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2015; 53(7):2103–8.

European directive 98/79/EC registration

Poster presentation SFMM congress 2023

Instructions For Use: Eng - Fra

Material Safety Data Sheet: Eng - Fra

Bordier Affinity Products SA, Chatanerie 2, Bâtiment Biokema, CH-1023 Crissier, Switzerland
Phone: + 41 21 633 31 67.  Fax: + 41 21 633 31 78. Email: cb(at)bordier.ch